{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T14:46:34Z","timestamp":1794581194259,"version":"4.9.1"},"reference-count":207,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T00:00:00Z","timestamp":1745539200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T00:00:00Z","timestamp":1745539200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Microbiol"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1038\/s41579-025-01181-y","type":"journal-article","created":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T06:24:54Z","timestamp":1745562294000},"page":"667-679","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":76,"title":["Epstein\u2013Barr virus pathogenesis and emerging control strategies"],"prefix":"10.1038","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6419-1940","authenticated-orcid":false,"given":"Christian","family":"M\u00fcnz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,25]]},"reference":[{"key":"1181_CR1","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1084\/jem.121.5.761","volume":"121","author":"MA Epstein","year":"1964","unstructured":"Epstein, M. A., Henle, G., Achong, B. G. & Barr, Y. M. Morphological and biological studies on a virus in cultured lymphoblasts from Burkitt\u2019s lymphoma. J. Exp. Med. 121, 761\u2013770 (1964).","journal-title":"J. Exp. Med."},{"key":"1181_CR2","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/S0140-6736(64)91524-7","volume":"1","author":"MA Epstein","year":"1964","unstructured":"Epstein, M. A., Achong, B. G. & Barr, Y. M. Virus particles in cultured lymphoblasts from Burkitt\u2019s lymphoma. Lancet 1, 702\u2013703 (1964).","journal-title":"Lancet"},{"key":"1181_CR3","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1146\/annurev-pathmechdis-012418-013023","volume":"14","author":"PJ Farrell","year":"2019","unstructured":"Farrell, P. J. Epstein\u2013Barr virus and cancer. Annu. Rev. Pathol. 14, 29\u201353 (2019).","journal-title":"Annu. Rev. Pathol."},{"key":"1181_CR4","doi-asserted-by":"publisher","first-page":"3652","DOI":"10.1016\/j.cell.2022.08.026","volume":"185","author":"B Damania","year":"2022","unstructured":"Damania, B., Kenney, S. C. & Raab-Traub, N. Epstein\u2013Barr virus: biology and clinical disease. Cell 185, 3652\u20133670 (2022).","journal-title":"Cell"},{"key":"1181_CR5","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1056\/NEJMra032015","volume":"350","author":"DA Thorley-Lawson","year":"2004","unstructured":"Thorley-Lawson, D. A. & Gross, A. Persistence of the Epstein\u2013Barr virus and the origins of associated lymphomas. N. Engl. J. Med. 350, 1328\u20131337 (2004).","journal-title":"N. Engl. J. Med."},{"key":"1181_CR6","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1038\/s41579-019-0249-7","volume":"17","author":"C M\u00fcnz","year":"2019","unstructured":"M\u00fcnz, C. Latency and lytic replication in the oncogenesis of the Epstein\u2013Barr virus. Nat. Rev. Microbiol. 17, 691\u2013700 (2019).","journal-title":"Nat. Rev. Microbiol."},{"key":"1181_CR7","first-page":"355","volume":"391","author":"ME Ressing","year":"2015","unstructured":"Ressing, M. E. et al. Immune evasion by Epstein\u2013Barr virus. Curr. Top. Microbiol. Immunol. 391, 355\u2013381 (2015).","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"1181_CR8","doi-asserted-by":"publisher","first-page":"955603","DOI":"10.3389\/fmicb.2022.955603","volume":"13","author":"M Albanese","year":"2022","unstructured":"Albanese, M., Tagawa, T. & Hammerschmidt, W. Strategies of Epstein\u2013Barr virus to evade innate antiviral immunity of its human host. Front. Microbiol. 13, 955603 (2022).","journal-title":"Front. Microbiol."},{"key":"1181_CR9","doi-asserted-by":"publisher","first-page":"e180","DOI":"10.1016\/S2214-109X(19)30488-7","volume":"8","author":"C de Martel","year":"2020","unstructured":"de Martel, C., Georges, D., Bray, F., Ferlay, J. & Clifford, G. M. Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis. Lancet Glob. Health 8, e180\u2013e190 (2020).","journal-title":"Lancet Glob. Health"},{"key":"1181_CR10","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s00432-021-03824-y","volume":"148","author":"Y Wong","year":"2022","unstructured":"Wong, Y., Meehan, M. T., Burrows, S. R., Doolan, D. L. & Miles, J. J. Estimating the global burden of Epstein\u2013Barr virus-related cancers. J. Cancer Res. Clin. Oncol. 148, 31\u201346 (2022).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"1181_CR11","doi-asserted-by":"publisher","first-page":"713","DOI":"10.3389\/fonc.2019.00713","volume":"9","author":"C Shannon-Lowe","year":"2019","unstructured":"Shannon-Lowe, C. & Rickinson, A. The global landscape of EBV-associated tumors. Front. Oncol. 9, 713 (2019).","journal-title":"Front. Oncol."},{"key":"1181_CR12","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1126\/science.abj8222","volume":"375","author":"K Bjornevik","year":"2022","unstructured":"Bjornevik, K. et al. Longitudinal analysis reveals high prevalence of Epstein\u2013Barr virus associated with multiple sclerosis. Science 375, 296\u2013301 (2022).","journal-title":"Science"},{"key":"1181_CR13","first-page":"160","volume":"19","author":"K Bjornevik","year":"2023","unstructured":"Bjornevik, K., M\u00fcnz, C., Cohen, J. I. & Ascherio, A. Epstein\u2013Barr virus as a leading cause of multiple sclerosis: mechanisms and implications. Nat. Rev. Neurol. 19, 160\u2013171 (2023).","journal-title":"Nat. Rev. Neurol."},{"key":"1181_CR14","doi-asserted-by":"publisher","DOI":"10.1172\/JCI179483","volume":"134","author":"JI Cohen","year":"2024","unstructured":"Cohen, J. I. Therapeutic vaccines for herpesviruses. J. Clin. Invest. 134, e179483 (2024).","journal-title":"J. Clin. Invest."},{"key":"1181_CR15","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1056\/NEJMoa2308917","volume":"390","author":"F Muller","year":"2024","unstructured":"Muller, F. et al. CD19 CAR T-cell therapy in autoimmune disease \u2014 a case series with follow-up. N. Engl. J. Med. 390, 687\u2013700 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1181_CR16","doi-asserted-by":"publisher","DOI":"10.1172\/JCI163548","volume":"133","author":"A Bonifacius","year":"2023","unstructured":"Bonifacius, A. et al. Patient-tailored adoptive immunotherapy with EBV-specific T cells from related and unrelated donors. J. Clin. Invest. 133, e163548 (2023).","journal-title":"J. Clin. Invest."},{"key":"1181_CR17","doi-asserted-by":"publisher","first-page":"8179","DOI":"10.1128\/JVI.00443-13","volume":"87","author":"SM Tugizov","year":"2013","unstructured":"Tugizov, S. M., Herrera, R. & Palefsky, J. M. Epstein\u2013Barr virus transcytosis through polarized oral epithelial cells. J. Virol. 87, 8179\u20138194 (2013).","journal-title":"J. Virol."},{"key":"1181_CR18","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/nm830","volume":"9","author":"SM Tugizov","year":"2003","unstructured":"Tugizov, S. M., Berline, J. W. & Palefsky, J. M. Epstein\u2013Barr virus infection of polarized tongue and nasopharyngeal epithelial cells. Nat. Med. 9, 307\u2013314 (2003).","journal-title":"Nat. Med."},{"key":"1181_CR19","doi-asserted-by":"publisher","first-page":"e01723","DOI":"10.1128\/mBio.01723-19","volume":"10","author":"D Pich","year":"2019","unstructured":"Pich, D. et al. First days in the life of naive human B lymphocytes infected with Epstein\u2013Barr virus. mBio 10, e01723-19 (2019).","journal-title":"mBio"},{"key":"1181_CR20","doi-asserted-by":"publisher","first-page":"16046","DOI":"10.1073\/pnas.1901314116","volume":"116","author":"P Mrozek-Gorska","year":"2019","unstructured":"Mrozek-Gorska, P. et al. Epstein\u2013Barr virus reprograms human B lymphocytes immediately in the prelatent phase of infection. Proc. Natl Acad. Sci. USA 116, 16046\u201316055 (2019).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1181_CR21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.0030404","volume":"3","author":"M Altmann","year":"2005","unstructured":"Altmann, M. & Hammerschmidt, W. Epstein\u2013Barr virus provides a new paradigm: a requirement for the immediate inhibition of apoptosis. PLoS Biol. 3, e404 (2005).","journal-title":"PLoS Biol."},{"key":"1181_CR22","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/0042-6822(91)90893-G","volume":"181","author":"C Alfieri","year":"1991","unstructured":"Alfieri, C., Birkenbach, M. & Kieff, E. Early events in Epstein\u2013Barr virus infection of human B lymphocytes. Virology 181, 595\u2013608 (1991).","journal-title":"Virology"},{"key":"1181_CR23","first-page":"35","volume":"391","author":"B Kempkes","year":"2015","unstructured":"Kempkes, B. & Ling, P. D. EBNA2 and its coactivator EBNA-LP. Curr. Top. Microbiol. Immunol. 391, 35\u201359 (2015).","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"1181_CR24","first-page":"61","volume":"391","author":"MJ Allday","year":"2015","unstructured":"Allday, M. J., Bazot, Q. & White, R. E. The EBNA3 family: two oncoproteins and a tumour suppressor that are central to the biology of EBV in B cells. Curr. Top. Microbiol. Immunol. 391, 61\u2013117 (2015).","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"1181_CR25","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S1074-7613(00)00049-2","volume":"13","author":"JG Babcock","year":"2000","unstructured":"Babcock, J. G., Hochberg, D. & Thorley-Lawson, A. D. The expression pattern of Epstein\u2013Barr virus latent genes in vivo is dependent upon the differentiation stage of the infected B cell. Immunity 13, 497\u2013506 (2000).","journal-title":"Immunity"},{"key":"1181_CR26","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.62586","volume":"10","author":"ED SoRelle","year":"2021","unstructured":"SoRelle, E. D. et al. Single-cell RNA-seq reveals transcriptomic heterogeneity mediated by host\u2013pathogen dynamics in lymphoblastoid cell lines. eLife 10, e62586 (2021).","journal-title":"eLife"},{"key":"1181_CR27","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/35095584","volume":"1","author":"DA Thorley-Lawson","year":"2001","unstructured":"Thorley-Lawson, D. A. Epstein\u2013Barr virus: exploiting the immune system. Nat. Rev. Immunol. 1, 75\u201382 (2001).","journal-title":"Nat. Rev. Immunol."},{"key":"1181_CR28","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1073\/pnas.2237267100","volume":"101","author":"D Hochberg","year":"2004","unstructured":"Hochberg, D. et al. Demonstration of the Burkitt\u2019s lymphoma Epstein\u2013Barr virus phenotype in dividing latently infected memory cells in vivo. Proc. Natl Acad. Sci. USA 101, 239\u2013244 (2004).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1181_CR29","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/S1074-7613(00)80622-6","volume":"9","author":"GJ Babcock","year":"1998","unstructured":"Babcock, G. J., Decker, L. L., Volk, M. & Thorley-Lawson, D. A. EBV persistence in memory B cells in vivo. Immunity 9, 395\u2013404 (1998).","journal-title":"Immunity"},{"key":"1181_CR30","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1128\/JVI.79.2.1296-1307.2005","volume":"79","author":"LL Laichalk","year":"2005","unstructured":"Laichalk, L. L. & Thorley-Lawson, D. A. Terminal differentiation into plasma cells initiates the replicative cycle of Epstein\u2013Barr virus in vivo. J. Virol. 79, 1296\u20131307 (2005).","journal-title":"J. Virol."},{"key":"1181_CR31","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1128\/JVI.02781-14","volume":"89","author":"JA Reusch","year":"2015","unstructured":"Reusch, J. A., Nawandar, D. M., Wright, K. L., Kenney, S. C. & Mertz, J. E. Cellular differentiation regulator BLIMP1 induces Epstein\u2013Barr virus lytic reactivation in epithelial and B cells by activating transcription from both the R and Z promoters. J. Virol. 89, 1731\u20131743 (2015).","journal-title":"J. Virol."},{"key":"1181_CR32","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1002902","volume":"8","author":"A Woellmer","year":"2012","unstructured":"Woellmer, A., Arteaga-Salas, J. M. & Hammerschmidt, W. BZLF1 governs CpG-methylated chromatin of Epstein\u2013Barr virus reversing epigenetic repression. PLoS Pathog. 8, e1002902 (2012).","journal-title":"PLoS Pathog."},{"key":"1181_CR33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1005286","volume":"11","author":"SK Dunmire","year":"2015","unstructured":"Dunmire, S. K., Grimm, J. M., Schmeling, D. O., Balfour, H. H. Jr. & Hogquist, K. A. The incubation period of primary Epstein\u2013Barr virus infection: viral dynamics and immunologic events. PLoS Pathog. 11, e1005286 (2015).","journal-title":"PLoS Pathog."},{"key":"1181_CR34","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1010886","volume":"18","author":"A Ali","year":"2022","unstructured":"Ali, A. et al. Rta is the principal activator of Epstein\u2013Barr virus epithelial lytic transcription. PLoS Pathog. 18, e1010886 (2022).","journal-title":"PLoS Pathog."},{"key":"1181_CR35","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1009783","volume":"17","author":"N Van Sciver","year":"2021","unstructured":"Van Sciver, N. et al. Hippo signaling effectors YAP and TAZ induce Epstein\u2013Barr virus (EBV) lytic reactivation through TEADs in epithelial cells. PLoS Pathog. 17, e1009783 (2021).","journal-title":"PLoS Pathog."},{"key":"1181_CR36","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1146\/annurev-immunol-032414-112326","volume":"33","author":"GS Taylor","year":"2015","unstructured":"Taylor, G. S., Long, H. M., Brooks, J. M., Rickinson, A. B. & Hislop, A. D. The immunology of Epstein\u2013Barr virus-induced disease. Annu. Rev. Immunol. 33, 787\u2013821 (2015).","journal-title":"Annu. Rev. Immunol."},{"key":"1181_CR37","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1093\/femsre\/fuy044","volume":"43","author":"B Damania","year":"2019","unstructured":"Damania, B. & M\u00fcnz, C. Immunodeficiencies that predispose to pathologies by human oncogenic gamma-herpesviruses. FEMS Microbiol. Rev. 43, 181\u2013192 (2019).","journal-title":"FEMS Microbiol. Rev."},{"key":"1181_CR38","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1008477","volume":"16","author":"N Caduff","year":"2020","unstructured":"Caduff, N. et al. Immunosuppressive FK506 treatment leads to more frequent EBV-associated lymphoproliferative disease in humanized mice. PLoS Pathog. 16, e1008477 (2020).","journal-title":"PLoS Pathog."},{"key":"1181_CR39","doi-asserted-by":"publisher","DOI":"10.26508\/lsa.202000640","volume":"3","author":"D McHugh","year":"2020","unstructured":"McHugh, D. et al. EBV renders B cells susceptible to HIV-1 in humanized mice. Life Sci. Alliance 3, e202000640 (2020).","journal-title":"Life Sci. Alliance"},{"key":"1181_CR40","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1182\/blood.2019000928","volume":"135","author":"SG Tangye","year":"2020","unstructured":"Tangye, S. G. & Latour, S. Primary immunodeficiencies reveal the molecular requirements for effective host defense against EBV infection. Blood 135, 644\u2013655 (2020).","journal-title":"Blood"},{"key":"1181_CR41","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1038\/s41586-024-07213-6","volume":"628","author":"E Martin","year":"2024","unstructured":"Martin, E. et al. Role of IL-27 in Epstein\u2013Barr virus infection revealed by IL-27RA deficiency. Nature 628, 620\u2013629 (2024).","journal-title":"Nature"},{"key":"1181_CR42","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/nm0402-379","volume":"8","author":"V Appay","year":"2002","unstructured":"Appay, V. et al. Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections. Nat. Med. 8, 379\u2013385 (2002).","journal-title":"Nat. Med."},{"key":"1181_CR43","doi-asserted-by":"publisher","first-page":"113250","DOI":"10.1016\/j.celrep.2023.113250","volume":"42","author":"F Schmidt","year":"2023","unstructured":"Schmidt, F. et al. In-depth analysis of human virus-specific CD8+ T cells delineates unique phenotypic signatures for T cell specificity prediction. Cell Rep. 42, 113250 (2023).","journal-title":"Cell Rep."},{"key":"1181_CR44","doi-asserted-by":"publisher","first-page":"3225","DOI":"10.1182\/blood.2020009482","volume":"137","author":"Y Deng","year":"2021","unstructured":"Deng, Y. et al. CD27 is required for protective lytic EBV antigen specific CD8+ T cell expansion. Blood 137, 3225\u20133236 (2021).","journal-title":"Blood"},{"key":"1181_CR45","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.173489","volume":"9","author":"D Kirchmeier","year":"2024","unstructured":"Kirchmeier, D. et al. Epstein Barr virus infection induces tissue-resident memory T cells in mucosal lymphoid tissues. JCI Insight 9, e173489 (2024).","journal-title":"JCI Insight"},{"key":"1181_CR46","doi-asserted-by":"publisher","first-page":"2533","DOI":"10.1182\/blood-2014-01-553024","volume":"124","author":"T Azzi","year":"2014","unstructured":"Azzi, T. et al. Role for early-differentiated natural killer cells in infectious mononucleosis. Blood 124, 2533\u20132543 (2014).","journal-title":"Blood"},{"key":"1181_CR47","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1016\/j.celrep.2013.11.041","volume":"5","author":"O Chijioke","year":"2013","unstructured":"Chijioke, O. et al. Human natural killer cells prevent infectious mononucleosis features by targeting lytic Epstein\u2013Barr virus infection. Cell Rep. 5, 1489\u20131498 (2013).","journal-title":"Cell Rep."},{"key":"1181_CR48","doi-asserted-by":"publisher","first-page":"109056","DOI":"10.1016\/j.celrep.2021.109056","volume":"35","author":"N Caduff","year":"2021","unstructured":"Caduff, N. et al. KSHV infection drives poorly cytotoxic CD56 negative natural killer cell differentiation in vivo upon KSHV\/EBV dual infection. Cell Rep. 35, 109056 (2021).","journal-title":"Cell Rep."},{"key":"1181_CR49","doi-asserted-by":"publisher","first-page":"1331730","DOI":"10.3389\/fimmu.2023.1331730","volume":"14","author":"J Zhang","year":"2023","unstructured":"Zhang, J. et al. LMP1 and EBNA2 constitute a minimal set of EBV genes for transformation of human B cells. Front. Immunol. 14, 1331730 (2023).","journal-title":"Front. Immunol."},{"key":"1181_CR50","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/s41572-022-00404-3","volume":"8","author":"C Lopez","year":"2022","unstructured":"Lopez, C. et al. Burkitt lymphoma. Nat. Rev. Dis. Primers\u00a08, 78 (2022).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"1181_CR51","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/j.cell.2015.07.019","volume":"162","author":"DF Robbiani","year":"2015","unstructured":"Robbiani, D. F. et al. Plasmodium infection promotes genomic instability and AID-dependent B cell lymphoma. Cell 162, 727\u2013737 (2015).","journal-title":"Cell"},{"key":"1181_CR52","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1038\/312449a0","volume":"312","author":"HC Whittle","year":"1984","unstructured":"Whittle, H. C. et al. T-cell control of Epstein\u2013Barr virus-infected B cells is lost during P. falciparum malaria. Nature 312, 449\u2013450 (1984).","journal-title":"Nature"},{"key":"1181_CR53","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1002\/ijc.24014","volume":"124","author":"AM Moormann","year":"2009","unstructured":"Moormann, A. M. et al. Children with endemic Burkitt lymphoma are deficient in EBNA1-specific IFN-\u03b3 T cell responses. Int. J. Cancer 124, 1721\u20131726 (2009).","journal-title":"Int. J. Cancer"},{"key":"1181_CR54","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1086\/428910","volume":"191","author":"AM Moormann","year":"2005","unstructured":"Moormann, A. M. et al. Exposure to holoendemic malaria results in elevated Epstein\u2013Barr virus loads in children. J. Infect. Dis. 191, 1233\u20131238 (2005).","journal-title":"J. Infect. Dis."},{"key":"1181_CR55","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/s41572-020-0189-6","volume":"6","author":"JM Connors","year":"2020","unstructured":"Connors, J. M. et al. Hodgkin lymphoma. Nat. Rev. Dis. Primers\u00a06, 61 (2020).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"1181_CR56","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1056\/NEJMoa023141","volume":"349","author":"H Hjalgrim","year":"2003","unstructured":"Hjalgrim, H. et al. Characteristics of Hodgkin\u2019s lymphoma after infectious mononucleosis. N. Engl. J. Med. 349, 1324\u20131332 (2003).","journal-title":"N. Engl. J. Med."},{"key":"1181_CR57","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1084\/jem.187.9.1395","volume":"187","author":"MF Callan","year":"1998","unstructured":"Callan, M. F. et al. Direct visualization of antigen-specific CD8+ T cells during the primary immune response to Epstein\u2013Barr virus In vivo. J. Exp. Med. 187, 1395\u20131402 (1998).","journal-title":"J. Exp. Med."},{"key":"1181_CR58","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1038\/nm0896-906","volume":"2","author":"MF Callan","year":"1996","unstructured":"Callan, M. F. et al. Large clonal expansions of CD8+ T cells in acute infectious mononucleosis. Nat. Med. 2, 906\u2013911 (1996).","journal-title":"Nat. Med."},{"key":"1181_CR59","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1182\/blood.2020005470","volume":"139","author":"E Cesarman","year":"2022","unstructured":"Cesarman, E., Chadburn, A. & Rubinstein, P. G. KSHV\/HHV8-mediated hematologic diseases. Blood 139, 1013\u20131025 (2022).","journal-title":"Blood"},{"key":"1181_CR60","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41571-021-00524-x","volume":"18","author":"KCW Wong","year":"2021","unstructured":"Wong, K. C. W. et al. Nasopharyngeal carcinoma: an evolving paradigm. Nat. Rev. Clin. Oncol. 18, 679\u2013695 (2021).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1181_CR61","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1038\/s41588-019-0436-5","volume":"51","author":"M Xu","year":"2019","unstructured":"Xu, M. et al. Genome sequencing analysis identifies Epstein\u2013Barr virus subtypes associated with high risk of nasopharyngeal carcinoma. Nat. Genet. 51, 1131\u20131136 (2019).","journal-title":"Nat. Genet."},{"key":"1181_CR62","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.1038\/s41564-019-0546-y","volume":"4","author":"Z Li","year":"2019","unstructured":"Li, Z. et al. Epstein\u2013Barr virus ncRNA from a nasopharyngeal carcinoma induces an inflammatory response that promotes virus production. Nat. Microbiol. 4, 2475\u20132486 (2019).","journal-title":"Nat. Microbiol."},{"key":"1181_CR63","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1097\/CCO.0000000000000889","volume":"34","author":"H Kimura","year":"2022","unstructured":"Kimura, H., de Leval, L., Cai, Q. & Kim, W. S. EBV-associated NK and T-cell lymphoid neoplasms. Curr. Opin. Oncol. 34, 422\u2013431 (2022).","journal-title":"Curr. Opin. Oncol."},{"key":"1181_CR64","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1080\/15513815.2021.2000533","volume":"41","author":"M Vij","year":"2022","unstructured":"Vij, M. et al. CARMIL2 immunodeficiency with Epstein Barr virus associated smooth muscle tumor (EBV-SMT). Report of a case with comprehensive review of literature. Fetal Pediatr. Pathol. 41, 1023\u20131034 (2022).","journal-title":"Fetal Pediatr. Pathol."},{"key":"1181_CR65","doi-asserted-by":"publisher","first-page":"4009","DOI":"10.1182\/blood-2011-10-385377","volume":"119","author":"RK Shaw","year":"2012","unstructured":"Shaw, R. K. et al. Bilateral adrenal EBV-associated smooth muscle tumors in a child with a natural killer cell deficiency. Blood 119, 4009\u20134012 (2012).","journal-title":"Blood"},{"key":"1181_CR66","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20211682","volume":"219","author":"B Fournier","year":"2022","unstructured":"Fournier, B. et al. Inherited TNFSF9 deficiency causes broad Epstein\u2013Barr virus infection with EBV+ smooth muscle tumors. J. Exp. Med. 219, e20211682 (2022).","journal-title":"J. Exp. Med."},{"key":"1181_CR67","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1182\/blood.2020005611","volume":"137","author":"PJ Collins","year":"2021","unstructured":"Collins, P. J. et al. Characterizing EBV-associated lymphoproliferative diseases and the role of myeloid-derived suppressor cells. Blood 137, 203\u2013215 (2021).","journal-title":"Blood"},{"key":"1181_CR68","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20192262","volume":"217","author":"B Fournier","year":"2020","unstructured":"Fournier, B. et al. Rapid identification and characterization of infected cells in blood during chronic active Epstein\u2013Barr virus infection. J. Exp. Med. 217, e20192262 (2020).","journal-title":"J. Exp. Med."},{"key":"1181_CR69","doi-asserted-by":"publisher","first-page":"e00813","DOI":"10.1128\/JVI.00813-18","volume":"92","author":"CB Coleman","year":"2018","unstructured":"Coleman, C. B. et al. Epstein\u2013Barr virus type 2 infects T cells and induces B cell lymphomagenesis in humanized mice. J. Virol. 92, e00813-18 (2018).","journal-title":"J. Virol."},{"key":"1181_CR70","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.00394-22","volume":"96","author":"W Wongwiwat","year":"2022","unstructured":"Wongwiwat, W. et al. Epstein\u2013Barr virus genome deletions in Epstein\u2013Barr virus-positive T\/NK cell lymphoproliferative diseases. J. Virol. 96, e0039422 (2022).","journal-title":"J. Virol."},{"key":"1181_CR71","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.jcv.2018.03.001","volume":"102","author":"SK Dunmire","year":"2018","unstructured":"Dunmire, S. K., Verghese, P. S. & Balfour, H. H. Jr. Primary Epstein\u2013Barr virus infection. J. Clin. Virol. 102, 84\u201392 (2018).","journal-title":"J. Clin. Virol."},{"key":"1181_CR72","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1093\/infdis\/jiv340","volume":"212","author":"A Panikkar","year":"2015","unstructured":"Panikkar, A. et al. Cytokine-mediated loss of blood dendritic cells during Epstein\u2013Barr virus-associated acute infectious mononucleosis: implication for immune dysregulation. J. Infect. Dis. 212, 1957\u20131961 (2015).","journal-title":"J. Infect. Dis."},{"key":"1181_CR73","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1004746","volume":"11","author":"S Jayasooriya","year":"2015","unstructured":"Jayasooriya, S. et al. Early virological and immunological events in asymptomatic Epstein\u2013Barr virus infection in African children. PLoS Pathog. 11, e1004746 (2015).","journal-title":"PLoS Pathog."},{"key":"1181_CR74","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1182\/bloodadvances.2018025536","volume":"3","author":"C Gujer","year":"2019","unstructured":"Gujer, C. et al. Plasmacytoid dendritic cells respond to Epstein\u2013Barr virus infection with a distinct type I interferon subtype profile. Blood Adv. 3, 1129\u20131144 (2019).","journal-title":"Blood Adv."},{"key":"1181_CR75","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1002\/eji.201242552","volume":"43","author":"M Severa","year":"2013","unstructured":"Severa, M. et al. EBV stimulates TLR- and autophagy-dependent pathways and impairs maturation in plasmacytoid dendritic cells: implications for viral immune escape. Eur. J. Immunol. 43, 147\u2013158 (2013).","journal-title":"Eur. J. Immunol."},{"key":"1181_CR76","doi-asserted-by":"publisher","first-page":"3620","DOI":"10.4049\/jimmunol.0903736","volume":"185","author":"S Fiola","year":"2010","unstructured":"Fiola, S., Gosselin, D., Takada, K. & Gosselin, J. TLR9 contributes to the recognition of EBV by primary monocytes and plasmacytoid dendritic cells. J. Immunol. 185, 3620\u20133631 (2010).","journal-title":"J. Immunol."},{"key":"1181_CR77","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1111\/j.1365-2141.2005.05452.x","volume":"129","author":"H Williams","year":"2005","unstructured":"Williams, H. et al. The immune response to primary EBV infection: a role for natural killer cells. Br. J. Haematol. 129, 266\u2013274 (2005).","journal-title":"Br. J. Haematol."},{"key":"1181_CR78","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1093\/infdis\/jis646","volume":"207","author":"HH Balfour Jr.","year":"2013","unstructured":"Balfour, H. H. Jr. et al. Behavioral, virologic, and immunologic factors associated with acquisition and severity of primary Epstein\u2013Barr virus infection in university students. J. Infect. Dis. 207, 80\u201388 (2013).","journal-title":"J. Infect. Dis."},{"key":"1181_CR79","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1128\/JVI.01777-06","volume":"81","author":"IY Pappworth","year":"2007","unstructured":"Pappworth, I. Y., Wang, E. C. & Rowe, M. The switch from latent to productive infection in Epstein\u2013Barr virus-infected B cells is associated with sensitization to NK cell killing. J. Virol. 81, 474\u2013482 (2007).","journal-title":"J. Virol."},{"key":"1181_CR80","doi-asserted-by":"publisher","first-page":"5194","DOI":"10.1128\/JVI.78.10.5194-5204.2004","volume":"78","author":"D Hochberg","year":"2004","unstructured":"Hochberg, D. et al. Acute infection with Epstein\u2013Barr virus targets and overwhelms the peripheral memory B-cell compartment with resting, latently infected cells. J. Virol. 78, 5194\u20135204 (2004).","journal-title":"J. Virol."},{"key":"1181_CR81","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1002\/ana.20820","volume":"59","author":"EL Thacker","year":"2006","unstructured":"Thacker, E. L., Mirzaei, F. & Ascherio, A. Infectious mononucleosis and risk for multiple sclerosis: a meta-analysis. Ann. Neurol. 59, 499\u2013503 (2006).","journal-title":"Ann. Neurol."},{"key":"1181_CR82","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/nrneurol.2016.187","volume":"13","author":"T Olsson","year":"2017","unstructured":"Olsson, T., Barcellos, L. F. & Alfredsson, L. Interactions between genetic, lifestyle and environmental risk factors for multiple sclerosis. Nat. Rev. Neurol. 13, 25\u201336 (2017).","journal-title":"Nat. Rev. Neurol."},{"key":"1181_CR83","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1002\/ana.21886","volume":"67","author":"JD L\u00fcnemann","year":"2010","unstructured":"L\u00fcnemann, J. D. et al. Elevated Epstein\u2013Barr virus-encoded nuclear antigen-1 immune responses predict conversion to multiple sclerosis. Ann. Neurol. 67, 159\u2013169 (2010).","journal-title":"Ann. Neurol."},{"key":"1181_CR84","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1177\/1352458514533843","volume":"20","author":"S Kvistad","year":"2014","unstructured":"Kvistad, S. et al. Antibodies to Epstein\u2013Barr virus and MRI disease activity in multiple sclerosis. Mult. Scler. 20, 1833\u20131840 (2014).","journal-title":"Mult. Scler."},{"key":"1181_CR85","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1172\/JCI200523661","volume":"115","author":"S Cepok","year":"2005","unstructured":"Cepok, S. et al. Identification of Epstein\u2013Barr virus proteins as putative targets of the immune response in multiple sclerosis. J. Clin. Invest. 115, 1352\u20131360 (2005).","journal-title":"J. Clin. Invest."},{"key":"1181_CR86","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/s41586-022-04432-7","volume":"603","author":"TV Lanz","year":"2022","unstructured":"Lanz, T. V. et al. Clonally expanded B cells in multiple sclerosis bind EBV EBNA1 and GlialCAM. Nature 603, 321\u2013327 (2022).","journal-title":"Nature"},{"key":"1181_CR87","doi-asserted-by":"publisher","first-page":"16955","DOI":"10.1073\/pnas.1902623116","volume":"116","author":"K Tengvall","year":"2019","unstructured":"Tengvall, K. et al. Molecular mimicry between Anoctamin 2 and Epstein\u2013Barr virus nuclear antigen 1 associates with multiple sclerosis risk. Proc. Natl Acad. Sci. USA 116, 16955\u201316960 (2019).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1181_CR88","doi-asserted-by":"publisher","first-page":"eadg3032","DOI":"10.1126\/sciadv.adg3032","volume":"9","author":"OG Thomas","year":"2023","unstructured":"Thomas, O. G. et al. Cross-reactive EBNA1 immunity targets alpha-crystallin B and is associated with multiple sclerosis. Sci. Adv. 9, eadg3032 (2023).","journal-title":"Sci. Adv."},{"key":"1181_CR89","doi-asserted-by":"publisher","first-page":"5705","DOI":"10.1016\/j.cell.2023.11.015","volume":"186","author":"H Vietzen","year":"2023","unstructured":"Vietzen, H. et al. Ineffective control of Epstein-Barr-virus-induced autoimmunity increases the risk for multiple sclerosis. Cell 186, 5705\u20135718.e13 (2023).","journal-title":"Cell"},{"key":"1181_CR90","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1146\/annurev-immunol-101320-125133","volume":"40","author":"NM Wilkinson","year":"2022","unstructured":"Wilkinson, N. M., Chen, H. C., Lechner, M. G. & Su, M. A. Sex differences in immunity. Annu. Rev. Immunol. 40, 75\u201394 (2022).","journal-title":"Annu. Rev. Immunol."},{"key":"1181_CR91","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1093\/brain\/awl067","volume":"129","author":"JD L\u00fcnemann","year":"2006","unstructured":"L\u00fcnemann, J. D. et al. Increased frequency and broadened specificity of latent EBV nuclear antigen-1-specific T cells in multiple sclerosis. Brain 129, 1493\u20131506 (2006).","journal-title":"Brain"},{"key":"1181_CR92","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1084\/jem.20072397","volume":"205","author":"JD L\u00fcnemann","year":"2008","unstructured":"L\u00fcnemann, J. D. et al. EBNA1-specific T cells from patients with multiple sclerosis cross react with myelin antigens and co-produce IFN-\u03b3 and IL-2. J. Exp. Med. 205, 1763\u20131773 (2008).","journal-title":"J. Exp. Med."},{"key":"1181_CR93","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1012177","volume":"20","author":"OG Thomas","year":"2024","unstructured":"Thomas, O. G. et al. Heightened Epstein\u2013Barr virus immunity and potential cross-reactivities in multiple sclerosis. PLoS Pathog. 20, e1012177 (2024).","journal-title":"PLoS Pathog."},{"key":"1181_CR94","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1093\/brain\/awn108","volume":"131","author":"S Jilek","year":"2008","unstructured":"Jilek, S. et al. Strong EBV-specific CD8+ T-cell response in patients with early multiple sclerosis. Brain 131, 1712\u20131721 (2008).","journal-title":"Brain"},{"key":"1181_CR95","doi-asserted-by":"publisher","first-page":"e00980","DOI":"10.1128\/JVI.00980-19","volume":"93","author":"B Serafini","year":"2019","unstructured":"Serafini, B., Rosicarelli, B., Veroni, C., Mazzola, G. A. & Aloisi, F. Epstein\u2013Barr virus-specific CD8 T cells selectively infiltrate the brain in multiple sclerosis and interact locally with virus-infected cells: clue for a virus-driven immunopathological mechanism. J. Virol. 93, e00980-19 (2019).","journal-title":"J. Virol."},{"key":"1181_CR96","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20220650","volume":"219","author":"T Schneider-Hohendorf","year":"2022","unstructured":"Schneider-Hohendorf, T. et al. Broader Epstein\u2013Barr virus-specific T cell receptor repertoire in patients with multiple sclerosis. J. Exp. Med. 219, e20220650 (2022).","journal-title":"J. Exp. Med."},{"key":"1181_CR97","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2315857121","volume":"121","author":"A Gottlieb","year":"2024","unstructured":"Gottlieb, A., Pham, H. P. T., Saltarrelli, J. G. & Lindsey, J. W. Expanded T lymphocytes in the cerebrospinal fluid of multiple sclerosis patients are specific for Epstein\u2013Barr-virus-infected B cells. Proc. Natl Acad. Sci. USA 121, e2315857121 (2024).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1181_CR98","doi-asserted-by":"publisher","first-page":"2899","DOI":"10.1084\/jem.20071030","volume":"204","author":"B Serafini","year":"2007","unstructured":"Serafini, B. et al. Dysregulated Epstein\u2013Barr virus infection in the multiple sclerosis brain. J. Exp. Med. 204, 2899\u20132912 (2007).","journal-title":"J. Exp. Med."},{"key":"1181_CR99","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1002\/eji.202048655","volume":"51","author":"H Zdimerova","year":"2021","unstructured":"Zdimerova, H. et al. Attenuated immune control of Epstein\u2013Barr virus in humanized mice is associated with the multiple sclerosis risk factor HLA-DR15. Eur. J. Immunol. 51, 64\u201375 (2021).","journal-title":"Eur. J. Immunol."},{"key":"1181_CR100","doi-asserted-by":"publisher","first-page":"578036","DOI":"10.1016\/j.jneuroim.2023.578036","volume":"376","author":"B Serafini","year":"2023","unstructured":"Serafini, B., Rosicarelli, B., Veroni, C. & Aloisi, F. Tissue-resident memory T cells in the multiple sclerosis brain and their relationship to Epstein\u2013Barr virus infected B cells. J. Neuroimmunol. 376, 578036 (2023).","journal-title":"J. Neuroimmunol."},{"key":"1181_CR101","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1172\/JCI111388","volume":"73","author":"G Tosato","year":"1984","unstructured":"Tosato, G. et al. Abnormally elevated frequency of Epstein\u2013Barr virus-infected B cells in the blood of patients with rheumatoid arthritis. J. Clin. Invest. 73, 1789\u20131795 (1984).","journal-title":"J. Clin. Invest."},{"key":"1181_CR102","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.4049\/jimmunol.131.4.1797","volume":"131","author":"GC Tsokos","year":"1983","unstructured":"Tsokos, G. C., Magrath, I. T. & Balow, J. E. Epstein\u2013Barr virus induces normal B cell responses but defective suppressor T cell responses in patients with systemic lupus erythematosus. J. Immunol. 131, 1797\u20131801 (1983).","journal-title":"J. Immunol."},{"key":"1181_CR103","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1111\/ajt.14020","volume":"17","author":"MA AlDabbagh","year":"2017","unstructured":"AlDabbagh, M. A. et al. The role of antiviral prophylaxis for the prevention of Epstein\u2013Barr virus-associated posttransplant lymphoproliferative disease in solid organ transplant recipients: a systematic review. Am. J. Transpl. 17, 770\u2013781 (2017).","journal-title":"Am. J. Transpl."},{"key":"1181_CR104","doi-asserted-by":"publisher","first-page":"3273","DOI":"10.1158\/1078-0432.CCR-17-2685","volume":"24","author":"JP Dugan","year":"2018","unstructured":"Dugan, J. P. et al. Complete and durable responses in primary central nervous system post-transplant lymphoproliferative disorder with zidovudine, ganciclovir, rituximab and dexamethasone. Clin. Cancer Res. 24, 3273\u20133281 (2018).","journal-title":"Clin. Cancer Res."},{"key":"1181_CR105","doi-asserted-by":"publisher","first-page":"6339","DOI":"10.1182\/bloodadvances.2023010330","volume":"7","author":"B Haverkos","year":"2023","unstructured":"Haverkos, B. et al. Targeted therapy with nanatinostat and valganciclovir in recurrent EBV-positive lymphoid malignancies: a phase 1b\/2 study. Blood Adv. 7, 6339\u20136350 (2023).","journal-title":"Blood Adv."},{"key":"1181_CR106","doi-asserted-by":"publisher","first-page":"12368","DOI":"10.1073\/pnas.2002392117","volume":"117","author":"NC Drosu","year":"2020","unstructured":"Drosu, N. C., Edelman, E. R. & Housman, D. E. Tenofovir prodrugs potently inhibit Epstein\u2013Barr virus lytic DNA replication by targeting the viral DNA polymerase. Proc. Natl Acad. Sci. USA 117, 12368\u201312374 (2020).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1181_CR107","doi-asserted-by":"publisher","first-page":"105436","DOI":"10.1016\/j.msard.2024.105436","volume":"83","author":"O Torkildsen","year":"2024","unstructured":"Torkildsen, O., Myhr, K. M., Brugger-Synnes, P. & Bjornevik, K. Antiviral therapy with tenofovir in MS. Mult. Scler. Relat. Disord. 83, 105436 (2024).","journal-title":"Mult. Scler. Relat. Disord."},{"key":"1181_CR108","first-page":"3","volume":"391","author":"L Frappier","year":"2015","unstructured":"Frappier, L. Ebna1. Curr. Top. Microbiol. Immunol. 391, 3\u201334 (2015).","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"1181_CR109","doi-asserted-by":"publisher","first-page":"10989","DOI":"10.1073\/pnas.1832776100","volume":"100","author":"S Humme","year":"2003","unstructured":"Humme, S. et al. The EBV nuclear antigen 1 (EBNA1) enhances B cell immortalization several thousandfold. Proc. Natl Acad. Sci. USA 100, 10989\u201310994 (2003).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1181_CR110","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1177\/1087057110379154","volume":"15","author":"S Thompson","year":"2010","unstructured":"Thompson, S., Messick, T., Schultz, D. C., Reichman, M. & Lieberman, P. M. Development of a high-throughput screen for inhibitors of Epstein\u2013Barr virus EBNA1. J. Biomol. Screen. 15, 1107\u20131115 (2010).","journal-title":"J. Biomol. Screen."},{"key":"1181_CR111","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0010126","volume":"5","author":"N Li","year":"2010","unstructured":"Li, N. et al. Discovery of selective inhibitors against EBNA1 via high throughput in silico virtual screening. PLoS ONE 5, e10126 (2010).","journal-title":"PLoS ONE"},{"key":"1181_CR112","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/S0092-8674(00)81056-9","volume":"84","author":"A Bochkarev","year":"1996","unstructured":"Bochkarev, A. et al. Crystal structure of the DNA-binding domain of the Epstein\u2013Barr virus origin-binding protein, EBNA1, bound to DNA. Cell 84, 791\u2013800 (1996).","journal-title":"Cell"},{"key":"1181_CR113","doi-asserted-by":"publisher","first-page":"eaau5612","DOI":"10.1126\/scitranslmed.aau5612","volume":"11","author":"TE Messick","year":"2019","unstructured":"Messick, T. E. et al. Structure-based design of small-molecule inhibitors of EBNA1 DNA binding blocks Epstein\u2013Barr virus latent infection and tumor growth. Sci. Transl Med. 11, eaau5612 (2019).","journal-title":"Sci. Transl Med."},{"key":"1181_CR114","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1007\/s10120-021-01193-6","volume":"24","author":"SS Soldan","year":"2021","unstructured":"Soldan, S. S. et al. EBNA1 inhibitors have potent and selective antitumor activity in xenograft models of Epstein\u2013Barr virus-associated gastric cancer. Gastric Cancer 24, 1076\u20131088 (2021).","journal-title":"Gastric Cancer"},{"key":"1181_CR115","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200149","volume":"10","author":"MCG Monaco","year":"2019","unstructured":"Monaco, M. C. G. et al. EBNA1 inhibitors block proliferation of spontaneous lymphoblastoid cell lines from patients with multiple sclerosis and healthy controls. Neurol. Neuroimmunol. Neuroinflamm. 10, e200149 (2023).","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"1181_CR116","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1158\/1078-0432.CCR-24-2814","volume":"31","author":"AD Colevas","year":"2025","unstructured":"Colevas, A. D. et al. First-in-human clinical trial of a small molecule EBNA1 inhibitor, VK-2019, in patients with Epstein\u2013Barr positive nasopharyngeal cancer, with pharmacokinetic and pharmacodynamic studies. Clin. Cancer Res. 31, 815\u2013823 (2025).","journal-title":"Clin. Cancer Res."},{"key":"1181_CR117","doi-asserted-by":"publisher","first-page":"2859","DOI":"10.1128\/JVI.01628-10","volume":"85","author":"MS Kang","year":"2011","unstructured":"Kang, M. S. et al. Roscovitine inhibits EBNA1 serine 393 phosphorylation, nuclear localization, transcription, and episome maintenance. J. Virol. 85, 2859\u20132868 (2011).","journal-title":"J. Virol."},{"key":"1181_CR118","first-page":"119","volume":"391","author":"A Kieser","year":"2015","unstructured":"Kieser, A. & Sterz, K. R. The latent membrane protein 1 (LMP1). Curr. Top. Microbiol. Immunol. 391, 119\u2013149 (2015).","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"1181_CR119","doi-asserted-by":"publisher","DOI":"10.1038\/emm.2014.84","volume":"47","author":"MS Kang","year":"2015","unstructured":"Kang, M. S. & Kieff, E. Epstein\u2013Barr virus latent genes. Exp. Mol. Med. 47, e131 (2015).","journal-title":"Exp. Mol. Med."},{"key":"1181_CR120","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-44455-w","volume":"15","author":"F Giehler","year":"2024","unstructured":"Giehler, F. et al. Epstein\u2013Barr virus-driven B cell lymphoma mediated by a direct LMP1-TRAF6 complex. Nat. Commun. 15, 414 (2024).","journal-title":"Nat. Commun."},{"key":"1181_CR121","doi-asserted-by":"publisher","first-page":"eadk4898","DOI":"10.1126\/science.adk4898","volume":"385","author":"B Muller-Durovic","year":"2024","unstructured":"Muller-Durovic, B. et al. A metabolic dependency of EBV can be targeted to hinder B cell transformation. Science 385, eadk4898 (2024).","journal-title":"Science"},{"key":"1181_CR122","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1016\/j.immuni.2023.09.011","volume":"56","author":"I Mellman","year":"2023","unstructured":"Mellman, I., Chen, D. S., Powles, T. & Turley, S. J. The cancer\u2013immunity cycle: indication, genotype, and immunotype. Immunity 56, 2188\u20132205 (2023).","journal-title":"Immunity"},{"key":"1181_CR123","doi-asserted-by":"publisher","first-page":"15088","DOI":"10.1038\/nrdp.2015.88","volume":"2","author":"VR Dharnidharka","year":"2016","unstructured":"Dharnidharka, V. R. et al. Post-transplant lymphoproliferative disorders. Nat. Rev. Dis. Primers\u00a02, 15088 (2016).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"1181_CR124","first-page":"2208","volume":"94","author":"RE Curtis","year":"1999","unstructured":"Curtis, R. E. et al. Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. Blood 94, 2208\u20132216 (1999).","journal-title":"Blood"},{"key":"1181_CR125","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1093\/cid\/cit391","volume":"57","author":"J Styczynski","year":"2013","unstructured":"Styczynski, J. et al. Response to rituximab-based therapy and risk factor analysis in Epstein Barr virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Clin. Infect. Dis. 57, 794\u2013802 (2013).","journal-title":"Clin. Infect. Dis."},{"key":"1181_CR126","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1007\/s12325-017-0612-x","volume":"34","author":"G Salles","year":"2017","unstructured":"Salles, G. et al. Rituximab in B-cell hematologic malignancies: a review of 20 years of clinical experience. Adv. Ther. 34, 2232\u20132273 (2017).","journal-title":"Adv. Ther."},{"key":"1181_CR127","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1212\/WNL.0b013e3181e24373","volume":"74","author":"RT Naismith","year":"2010","unstructured":"Naismith, R. T. et al. Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: a 52-week phase II trial. Neurology 74, 1860\u20131867 (2010).","journal-title":"Neurology"},{"key":"1181_CR128","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1002\/ana.21867","volume":"66","author":"K Hawker","year":"2009","unstructured":"Hawker, K. et al. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann. Neurol. 66, 460\u2013471 (2009).","journal-title":"Ann. Neurol."},{"key":"1181_CR129","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1056\/NEJMoa0706383","volume":"358","author":"SL Hauser","year":"2008","unstructured":"Hauser, S. L. et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N. Engl. J. Med. 358, 676\u2013688 (2008).","journal-title":"N. Engl. J. Med."},{"key":"1181_CR130","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1056\/NEJMoa1606468","volume":"376","author":"X Montalban","year":"2017","unstructured":"Montalban, X. et al. Ocrelizumab versus placebo in primary progressive multiple sclerosis. N. Engl. J. Med. 376, 209\u2013220 (2017).","journal-title":"N. Engl. J. Med."},{"key":"1181_CR131","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa1601277","volume":"376","author":"SL Hauser","year":"2017","unstructured":"Hauser, S. L. et al. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N. Engl. J. Med. 376, 221\u2013234 (2017).","journal-title":"N. Engl. J. Med."},{"key":"1181_CR132","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","volume":"28","author":"A Mackensen","year":"2022","unstructured":"Mackensen, A. et al. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Nat. Med. 28, 2124\u20132132 (2022).","journal-title":"Nat. Med."},{"key":"1181_CR133","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/s41582-021-00498-5","volume":"17","author":"MT Cencioni","year":"2021","unstructured":"Cencioni, M. T., Mattoscio, M., Magliozzi, R., Bar-Or, A. & Muraro, P. A. B cells in multiple sclerosis \u2014 from targeted depletion to immune reconstitution therapies. Nat. Rev. Neurol. 17, 399\u2013414 (2021).","journal-title":"Nat. Rev. Neurol."},{"key":"1181_CR134","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.jneuroim.2014.08.617","volume":"276","author":"V Studer","year":"2014","unstructured":"Studer, V., Rossi, S., Motta, C., Buttari, F. & Centonze, D. Peripheral B cell depletion and central proinflammatory cytokine reduction following repeated intrathecal administration of rituximab in progressive multiple sclerosis. J. Neuroimmunol. 276, 229\u2013231 (2014).","journal-title":"J. Neuroimmunol."},{"key":"1181_CR135","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1001\/archneurol.2010.99","volume":"67","author":"L Piccio","year":"2010","unstructured":"Piccio, L. et al. Changes in B- and T-lymphocyte and chemokine levels with rituximab treatment in multiple sclerosis. Arch. Neurol. 67, 707\u2013714 (2010).","journal-title":"Arch. Neurol."},{"key":"1181_CR136","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200211","volume":"11","author":"A Langer-Gould","year":"2024","unstructured":"Langer-Gould, A., Li, B. H., Smith, J. B. & Xu, S. Multiple sclerosis, rituximab, hypogammaglobulinemia, and risk of infections. Neurol. Neuroimmunol. Neuroinflamm 11, e200211 (2024).","journal-title":"Neurol. Neuroimmunol. Neuroinflamm"},{"key":"1181_CR137","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.3109\/10428194.2011.574761","volume":"52","author":"YE Deutsch","year":"2011","unstructured":"Deutsch, Y. E., Tadmor, T., Podack, E. R. & Rosenblatt, J. D. CD30: an important new target in hematologic malignancies. Leuk. Lymphoma 52, 1641\u20131654 (2011).","journal-title":"Leuk. Lymphoma"},{"key":"1181_CR138","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","volume":"30","author":"A Younes","year":"2012","unstructured":"Younes, A. et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin\u2019s lymphoma. J. Clin. Oncol. 30, 2183\u20132189 (2012).","journal-title":"J. Clin. Oncol."},{"key":"1181_CR139","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(15)60165-9","volume":"385","author":"CH Moskowitz","year":"2015","unstructured":"Moskowitz, C. H. et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin\u2019s lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 385, 1853\u20131862 (2015).","journal-title":"Lancet"},{"key":"1181_CR140","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1182\/blood-2014-09-598763","volume":"125","author":"ED Jacobsen","year":"2015","unstructured":"Jacobsen, E. D. et al. Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed\/refractory DLBCL with variable CD30 expression. Blood 125, 1394\u20131402 (2015).","journal-title":"Blood"},{"key":"1181_CR141","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/1756-8722-7-24","volume":"7","author":"NL Bartlett","year":"2014","unstructured":"Bartlett, N. L. et al. Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies. J. Hematol. Oncol. 7, 24 (2014).","journal-title":"J. Hematol. Oncol."},{"key":"1181_CR142","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1200\/JCO.2011.38.0402","volume":"30","author":"B Pro","year":"2012","unstructured":"Pro, B. et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J. Clin. Oncol. 30, 2190\u20132196 (2012).","journal-title":"J. Clin. Oncol."},{"key":"1181_CR143","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/S0140-6736(17)31266-7","volume":"390","author":"HM Prince","year":"2017","unstructured":"Prince, H. M. et al. Brentuximab vedotin or physician\u2019s choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. Lancet 390, 555\u2013566 (2017).","journal-title":"Lancet"},{"key":"1181_CR144","doi-asserted-by":"publisher","first-page":"254","DOI":"10.5045\/br.2015.50.4.254","volume":"50","author":"HK Kim","year":"2015","unstructured":"Kim, H. K. et al. Complete remission in CD30-positive refractory extranodal NK\/T-cell lymphoma with brentuximab vedotin. Blood Res. 50, 254\u2013256 (2015).","journal-title":"Blood Res."},{"key":"1181_CR145","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1007\/s00277-016-2627-9","volume":"95","author":"LM Poon","year":"2016","unstructured":"Poon, L. M. & Kwong, Y. L. Complete remission of refractory disseminated NK\/T cell lymphoma with brentuximab vedotin and bendamustine. Ann. Hematol. 95, 847\u2013849 (2016).","journal-title":"Ann. Hematol."},{"key":"1181_CR146","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1411087","volume":"372","author":"SM Ansell","year":"2015","unstructured":"Ansell, S. M. et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma. N. Engl. J. Med. 372, 311\u2013319 (2015).","journal-title":"N. Engl. J. Med."},{"key":"1181_CR147","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1016\/S1470-2045(18)30495-9","volume":"19","author":"W Fang","year":"2018","unstructured":"Fang, W. et al. Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials. Lancet Oncol. 19, 1338\u20131350 (2018).","journal-title":"Lancet Oncol."},{"key":"1181_CR148","doi-asserted-by":"publisher","first-page":"101594","DOI":"10.1016\/j.xcrm.2024.101594","volume":"5","author":"W Jiang","year":"2024","unstructured":"Jiang, W. et al. Enhancing efficacy and reducing toxicity: therapeutic optimization in locoregionally advanced nasopharyngeal carcinoma. Cell Rep. Med. 5, 101594 (2024).","journal-title":"Cell Rep. Med."},{"key":"1181_CR149","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1007748","volume":"15","author":"B Chatterjee","year":"2019","unstructured":"Chatterjee, B. et al. CD8+ T cells retain protective functions despite sustained inhibitory receptor expression during Epstein\u2013Barr virus infection in vivo. PLoS Pathog. 15, e1007748 (2019).","journal-title":"PLoS Pathog."},{"key":"1181_CR150","doi-asserted-by":"publisher","first-page":"614876","DOI":"10.3389\/fonc.2020.614876","volume":"10","author":"V Volk","year":"2020","unstructured":"Volk, V. et al. PD-1 blockade aggravates Epstein\u2013Barr virus+ post-transplant lymphoproliferative disorder in humanized mice resulting in central nervous system involvement and CD4+ T cell dysregulations. Front. Oncol. 10, 614876 (2020).","journal-title":"Front. Oncol."},{"key":"1181_CR151","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1038\/s41591-019-0523-2","volume":"25","author":"DB Johnson","year":"2019","unstructured":"Johnson, D. B. et al. A case report of clonal EBV-like memory CD4+ T cell activation in fatal checkpoint inhibitor-induced encephalitis. Nat. Med. 25, 1243\u20131250 (2019).","journal-title":"Nat. Med."},{"key":"1181_CR152","doi-asserted-by":"publisher","unstructured":"Matsumura, T. et al. Lymphoproliferative disorder in an esophageal cancer patient treated with pembrolizumab. Intern. Med. https:\/\/doi.org\/10.2169\/internalmedicine.3743-24 (2024).","DOI":"10.2169\/internalmedicine.3743-24"},{"key":"1181_CR153","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1056\/NEJM199409083311017","volume":"331","author":"HE Heslop","year":"1994","unstructured":"Heslop, H. E., Brenner, M. K. & Rooney, C. M. Donor T cells to treat EBV-associated lymphoma. N. Engl. J. Med. 331, 679\u2013680 (1994).","journal-title":"N. Engl. J. Med."},{"key":"1181_CR154","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1056\/NEJM199404283301703","volume":"330","author":"EB Papadopoulos","year":"1994","unstructured":"Papadopoulos, E. B. et al. Infusions of donor leukocytes to treat Epstein\u2013Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N. Engl. J. Med. 330, 1185\u20131191 (1994).","journal-title":"N. Engl. J. Med."},{"key":"1181_CR155","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1146\/annurev.immunol.25.022106.141527","volume":"25","author":"AM Leen","year":"2007","unstructured":"Leen, A. M., Rooney, C. M. & Foster, A. E. Improving T cell therapy for cancer. Annu. Rev. Immunol. 25, 243\u2013265 (2007).","journal-title":"Annu. Rev. Immunol."},{"key":"1181_CR156","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1182\/blood-2009-03-213256","volume":"114","author":"PJ Hanley","year":"2009","unstructured":"Hanley, P. J. et al. Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes. Blood 114, 1958\u20131967 (2009).","journal-title":"Blood"},{"key":"1181_CR157","doi-asserted-by":"publisher","first-page":"242ra283","DOI":"10.1126\/scitranslmed.3008825","volume":"6","author":"A Papadopoulou","year":"2014","unstructured":"Papadopoulou, A. et al. Activity of broad-spectrum T cells as treatment for AdV, EBV, CMV, BKV, and HHV6 infections after HSCT. Sci. Transl Med. 6, 242ra283 (2014).","journal-title":"Sci. Transl Med."},{"key":"1181_CR158","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1097\/00002371-200407000-00008","volume":"27","author":"CM Bollard","year":"2004","unstructured":"Bollard, C. M. et al. The generation and characterization of LMP2-specific CTLs for use as adoptive transfer from patients with relapsed EBV-positive Hodgkin disease. J. Immunother. 27, 317\u2013327 (2004).","journal-title":"J. Immunother."},{"key":"1181_CR159","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1200\/JCO.2013.51.5304","volume":"32","author":"CM Bollard","year":"2014","unstructured":"Bollard, C. M. et al. Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein\u2013Barr virus latent membrane proteins. J. Clin. Oncol. 32, 798\u2013808 (2014).","journal-title":"J. Clin. Oncol."},{"key":"1181_CR160","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1200\/JCO.2011.39.8495","volume":"31","author":"V Icheva","year":"2013","unstructured":"Icheva, V. et al. Adoptive transfer of Epstein\u2013Barr virus (EBV) nuclear antigen 1-specific T cells as treatment for EBV reactivation and lymphoproliferative disorders after allogeneic stem-cell transplantation. J. Clin. Oncol. 31, 39\u201348 (2013).","journal-title":"J. Clin. Oncol."},{"key":"1181_CR161","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1080\/14653240701320288","volume":"9","author":"DJ Moss","year":"2007","unstructured":"Moss, D. J., Khanna, R. & Gandhi, M. The use of T-cell directed cellular therapies in Australia. Cytotherapy 9, 222\u2013224 (2007).","journal-title":"Cytotherapy"},{"key":"1181_CR162","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1177\/1352458514521888","volume":"20","author":"MP Pender","year":"2014","unstructured":"Pender, M. P. et al. Epstein\u2013Barr virus-specific adoptive immunotherapy for progressive multiple sclerosis. Mult. Scler. 20, 1541\u20131544 (2014).","journal-title":"Mult. Scler."},{"key":"1181_CR163","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.124714","volume":"3","author":"MP Pender","year":"2018","unstructured":"Pender, M. P. et al. Epstein\u2013Barr virus-specific T cell therapy for progressive multiple sclerosis. JCI Insight 3, e124717 (2018).","journal-title":"JCI Insight"},{"key":"1181_CR164","doi-asserted-by":"publisher","first-page":"5113","DOI":"10.1182\/blood-2013-02-486324","volume":"121","author":"AM Leen","year":"2013","unstructured":"Leen, A. M. et al. Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation. Blood 121, 5113\u20135123 (2013).","journal-title":"Blood"},{"key":"1181_CR165","doi-asserted-by":"publisher","first-page":"2644","DOI":"10.1182\/blood-2011-08-371971","volume":"119","author":"E Doubrovina","year":"2012","unstructured":"Doubrovina, E. et al. Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation. Blood 119, 2644\u20132656 (2012).","journal-title":"Blood"},{"key":"1181_CR166","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/s41409-019-0614-1","volume":"54","author":"RJ O\u2019Reilly","year":"2019","unstructured":"O\u2019Reilly, R. J., Prockop, S., Hasan, A. & Doubrovina, E. Therapeutic advantages provided by banked virus-specific T-cells of defined HLA-restriction. Bone Marrow Transpl. 54, 759\u2013764 (2019).","journal-title":"Bone Marrow Transpl."},{"key":"1181_CR167","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1182\/blood-2006-12-063008","volume":"110","author":"T Haque","year":"2007","unstructured":"Haque, T. et al. Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. Blood 110, 1123\u20131131 (2007).","journal-title":"Blood"},{"key":"1181_CR168","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/S0140-6736(02)09672-1","volume":"360","author":"T Haque","year":"2002","unstructured":"Haque, T. et al. Treatment of Epstein\u2013Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells. Lancet 360, 436\u2013442 (2002).","journal-title":"Lancet"},{"key":"1181_CR169","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001608","volume":"9","author":"D Sinha","year":"2021","unstructured":"Sinha, D. et al. \u2018Off-the-shelf\u2019 allogeneic antigen-specific adoptive T-cell therapy for the treatment of multiple EBV-associated malignancies. J. Immunother. Cancer 9, e001608 (2021).","journal-title":"J. Immunother. Cancer"},{"key":"1181_CR170","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1200\/JCO.2017.74.3179","volume":"36","author":"CM Bollard","year":"2018","unstructured":"Bollard, C. M. et al. Tumor-specific T-cells engineered to overcome tumor immune evasion induce clinical responses in patients with relapsed hodgkin lymphoma. J. Clin. Oncol. 36, 1128\u20131139 (2018).","journal-title":"J. Clin. Oncol."},{"key":"1181_CR171","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-021-00162-7","volume":"5","author":"C Smith","year":"2021","unstructured":"Smith, C. et al. Complete response to PD-1 blockade following EBV-specific T-cell therapy in metastatic nasopharyngeal carcinoma. npj Precis. Oncol. 5, 24 (2021).","journal-title":"npj Precis. Oncol."},{"key":"1181_CR172","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.1182\/blood-2006-04-015164","volume":"108","author":"MK Gandhi","year":"2006","unstructured":"Gandhi, M. K. et al. Expression of LAG-3 by tumor-infiltrating lymphocytes is coincident with the suppression of latent membrane antigen-specific CD8+ T-cell function in Hodgkin lymphoma patients. Blood 108, 2280\u20132289 (2006).","journal-title":"Blood"},{"key":"1181_CR173","doi-asserted-by":"publisher","first-page":"eado2048","DOI":"10.1126\/sciadv.ado2048","volume":"10","author":"D Paliannina","year":"2024","unstructured":"Paliannina, D. et al. Stem cell memory EBV-specific T cells control EBV tumor growth and persist in vivo. Sci. Adv. 10, eado2048 (2024).","journal-title":"Sci. Adv."},{"key":"1181_CR174","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1158\/0008-5472.CAN-12-2448","volume":"73","author":"EP Hui","year":"2013","unstructured":"Hui, E. P. et al. Phase I trial of recombinant modified vaccinia ankara encoding Epstein\u2013Barr viral tumor antigens in nasopharyngeal carcinoma patients. Cancer Res. 73, 1676\u20131688 (2013).","journal-title":"Cancer Res."},{"key":"1181_CR175","doi-asserted-by":"publisher","first-page":"5009","DOI":"10.1158\/1078-0432.CCR-14-1122-T","volume":"20","author":"GS Taylor","year":"2014","unstructured":"Taylor, G. S. et al. A recombinant modified vaccinia ankara vaccine encoding Epstein\u2013Barr virus (EBV) target antigens: a phase I trial in UK patients with EBV-positive cancer. Clin. Cancer Res. 20, 5009\u20135022 (2014).","journal-title":"Clin. Cancer Res."},{"key":"1181_CR176","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1172\/JCI125364","volume":"129","author":"J R\u00fchl","year":"2019","unstructured":"R\u00fchl, J. et al. Heterologous prime-boost vaccination protects from EBV antigen expressing lymphomas. J. Clin. Invest. 129, 2071\u20132087 (2019).","journal-title":"J. Clin. Invest."},{"key":"1181_CR177","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.4049\/jimmunol.169.3.1593","volume":"169","author":"C Paludan","year":"2002","unstructured":"Paludan, C. et al. EBNA1 specific CD4+ Th1 cells kill Burkitt\u2019s lymphoma cells. J. Immunol. 169, 1593\u20131603 (2002).","journal-title":"J. Immunol."},{"key":"1181_CR178","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1182\/blood-2008-03-148072","volume":"112","author":"C Gurer","year":"2008","unstructured":"Gurer, C. et al. Targeting the nuclear antigen 1 of Epstein\u2013Barr virus to the human endocytic receptor DEC-205 stimulates protective T-cell responses. Blood 112, 1231\u20131239 (2008).","journal-title":"Blood"},{"key":"1181_CR179","doi-asserted-by":"publisher","first-page":"5034","DOI":"10.1182\/blood-2012-12-473413","volume":"121","author":"S Meixlsperger","year":"2013","unstructured":"Meixlsperger, S. et al. CD141+ dendritic cells produce prominent amounts of IFN-\u03b1 after dsRNA recognition and can be targeted via DEC-205 in humanized mice. Blood 121, 5034\u20135044 (2013).","journal-title":"Blood"},{"key":"1181_CR180","doi-asserted-by":"publisher","DOI":"10.1002\/eji.202250313","volume":"53","author":"F L\u00e4derach","year":"2023","unstructured":"L\u00e4derach, F. et al. MHC class II-deficient mice allow functional human CD4+ T-cell development. Eur. J. Immunol. 53, e2250313 (2023).","journal-title":"Eur. J. Immunol."},{"key":"1181_CR181","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1007464","volume":"14","author":"DG van Zyl","year":"2018","unstructured":"van Zyl, D. G. et al. Immunogenic particles with a broad antigenic spectrum stimulate cytolytic T cells and offer increased protection against EBV infection ex vivo and in mice. PLoS Pathog. 14, e1007464 (2018).","journal-title":"PLoS Pathog."},{"key":"1181_CR182","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-39770-1","volume":"14","author":"V Dasari","year":"2023","unstructured":"Dasari, V. et al. Lymph node targeted multi-epitope subunit vaccine promotes effective immunity to EBV in HLA-expressing mice. Nat. Commun. 14, 4371 (2023).","journal-title":"Nat. Commun."},{"key":"1181_CR183","doi-asserted-by":"publisher","first-page":"4697","DOI":"10.1016\/j.vaccine.2007.04.008","volume":"25","author":"M Moutschen","year":"2007","unstructured":"Moutschen, M. et al. Phase I\/II studies to evaluate safety and immunogenicity of a recombinant gp350 Epstein\u2013Barr virus vaccine in healthy adults. Vaccine 25, 4697\u20134705 (2007).","journal-title":"Vaccine"},{"key":"1181_CR184","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1086\/523813","volume":"196","author":"EM Sokal","year":"2007","unstructured":"Sokal, E. M. et al. Recombinant gp350 vaccine for infectious mononucleosis: a phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of an Epstein\u2013Barr virus vaccine in healthy young adults. J. Infect. Dis. 196, 1749\u20131753 (2007).","journal-title":"J. Infect. Dis."},{"key":"1181_CR185","doi-asserted-by":"publisher","first-page":"3039","DOI":"10.1016\/j.vaccine.2013.04.071","volume":"31","author":"X Cui","year":"2013","unstructured":"Cui, X. et al. A novel tetrameric gp350 1-470 as a potential Epstein\u2013Barr virus vaccine. Vaccine 31, 3039\u20133045 (2013).","journal-title":"Vaccine"},{"key":"1181_CR186","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/j.cell.2015.07.043","volume":"162","author":"M Kanekiyo","year":"2015","unstructured":"Kanekiyo, M. et al. Rational design of an Epstein\u2013Barr virus vaccine targeting the receptor-binding site. Cell 162, 1090\u20131100 (2015).","journal-title":"Cell"},{"key":"1181_CR187","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-015-0415-2","volume":"13","author":"JG Ogembo","year":"2015","unstructured":"Ogembo, J. G. et al. A chimeric EBV gp350\/220-based VLP replicates the virion B-cell attachment mechanism and elicits long-lasting neutralizing antibodies in mice. J. Transl. Med. 13, 50 (2015).","journal-title":"J. Transl. Med."},{"key":"1181_CR188","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1016\/j.immuni.2019.03.010","volume":"50","author":"W Bu","year":"2019","unstructured":"Bu, W. et al. Immunization with components of the viral fusion apparatus elicits antibodies that neutralize Epstein\u2013Barr virus in B cells and epithelial cells. Immunity 50, 1305\u20131316.e1306 (2019).","journal-title":"Immunity"},{"key":"1181_CR189","doi-asserted-by":"publisher","first-page":"4050","DOI":"10.1016\/j.vaccine.2016.06.021","volume":"34","author":"X Cui","year":"2016","unstructured":"Cui, X. et al. Rabbits immunized with Epstein\u2013Barr virus gH\/gL or gB recombinant proteins elicit higher serum virus neutralizing activity than gp350. Vaccine 34, 4050\u20134055 (2016).","journal-title":"Vaccine"},{"key":"1181_CR190","doi-asserted-by":"publisher","first-page":"eabf3685","DOI":"10.1126\/scitranslmed.abf3685","volume":"14","author":"CJ Wei","year":"2022","unstructured":"Wei, C. J. et al. A bivalent Epstein\u2013Barr virus vaccine induces neutralizing antibodies that block infection and confer immunity in humanized mice. Sci. Transl Med. 14, eabf3685 (2022).","journal-title":"Sci. Transl Med."},{"key":"1181_CR191","doi-asserted-by":"publisher","first-page":"285","DOI":"10.3390\/vaccines9030285","volume":"9","author":"X Cui","year":"2021","unstructured":"Cui, X. et al. Immunization with Epstein\u2013Barr virus core fusion machinery envelope proteins elicit high titers of neutralizing activities and protect humanized mice from lethal dose EBV challenge. Vaccines 9, 285 (2021).","journal-title":"Vaccines"},{"key":"1181_CR192","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1016\/j.chom.2023.09.011","volume":"31","author":"C Sun","year":"2023","unstructured":"Sun, C. et al. A gB nanoparticle vaccine elicits a protective neutralizing antibody response against EBV. Cell Host Microbe 31, 1882\u20131897.e10 (2023).","journal-title":"Cell Host Microbe"},{"key":"1181_CR193","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-49546-w","volume":"15","author":"L Zhong","year":"2024","unstructured":"Zhong, L. et al. A cocktail nanovaccine targeting key entry glycoproteins elicits high neutralizing antibody levels against EBV infection. Nat. Commun. 15, 5310 (2024).","journal-title":"Nat. Commun."},{"key":"1181_CR194","doi-asserted-by":"publisher","first-page":"1445209","DOI":"10.3389\/fimmu.2024.1445209","volume":"15","author":"GM Escalante","year":"2024","unstructured":"Escalante, G. M. et al. Multivalent MVA-vectored vaccine elicits EBV neutralizing antibodies in rhesus macaques that reduce EBV infection in humanized mice. Front. Immunol. 15, 1445209 (2024).","journal-title":"Front. Immunol."},{"key":"1181_CR195","doi-asserted-by":"publisher","first-page":"7065","DOI":"10.1073\/pnas.0510512103","volume":"103","author":"CD Shannon-Lowe","year":"2006","unstructured":"Shannon-Lowe, C. D., Neuhierl, B., Baldwin, G., Rickinson, A. B. & Delecluse, H. J. Resting B cells as a transfer vehicle for Epstein\u2013Barr virus infection of epithelial cells. Proc. Natl Acad. Sci. USA 103, 7065\u20137070 (2006).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1181_CR196","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1001338","volume":"7","author":"C Shannon-Lowe","year":"2011","unstructured":"Shannon-Lowe, C. & Rowe, M. Epstein\u2013Barr virus infection of polarized epithelial cells via the basolateral surface by memory B cell-mediated transfer infection. PLoS Pathog. 7, e1001338 (2011).","journal-title":"PLoS Pathog."},{"key":"1181_CR197","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/s41579-020-00448-w","volume":"19","author":"SA Connolly","year":"2021","unstructured":"Connolly, S. A., Jardetzky, T. S. & Longnecker, R. The structural basis of herpesvirus entry. Nat. Rev. Microbiol. 19, 110\u2013121 (2021).","journal-title":"Nat. Rev. Microbiol."},{"key":"1181_CR198","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1038\/nm0602-594","volume":"8","author":"CM Borza","year":"2002","unstructured":"Borza, C. M. & Hutt-Fletcher, L. M. Alternate replication in B cells and epithelial cells switches tropism of Epstein\u2013Barr virus. Nat. Med. 8, 594\u2013599 (2002).","journal-title":"Nat. Med."},{"key":"1181_CR199","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1038\/s41564-017-0081-7","volume":"3","author":"J Chen","year":"2018","unstructured":"Chen, J. et al. Ephrin receptor A2 is a functional entry receptor for Epstein\u2013Barr virus. Nat. Microbiol. 3, 172\u2013180 (2018).","journal-title":"Nat. Microbiol."},{"key":"1181_CR200","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41564-017-0080-8","volume":"3","author":"H Zhang","year":"2018","unstructured":"Zhang, H. et al. Ephrin receptor A2 is an epithelial cell receptor for Epstein\u2013Barr virus entry. Nat. Microbiol. 3, 1\u20138 (2018).","journal-title":"Nat. Microbiol."},{"key":"1181_CR201","doi-asserted-by":"publisher","first-page":"14421","DOI":"10.1073\/pnas.1921139117","volume":"117","author":"T Sommermann","year":"2020","unstructured":"Sommermann, T. et al. Functional interplay of Epstein\u2013Barr virus oncoproteins in a mouse model of B cell lymphomagenesis. Proc. Natl Acad. Sci. USA 117, 14421\u201314432 (2020).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1181_CR202","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1007179","volume":"14","author":"JA Bristol","year":"2018","unstructured":"Bristol, J. A. et al. A cancer-associated Epstein\u2013Barr virus BZLF1 promoter variant enhances lytic infection. PLoS Pathog. 14, e1007179 (2018).","journal-title":"PLoS Pathog."},{"key":"1181_CR203","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1038\/s41564-018-0334-0","volume":"4","author":"Y Okuno","year":"2019","unstructured":"Okuno, Y. et al. Defective Epstein\u2013Barr virus in chronic active infection and haematological malignancy. Nat. Microbiol. 4, 404\u2013413 (2019).","journal-title":"Nat. Microbiol."},{"key":"1181_CR204","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1128\/JVI.01512-10","volume":"85","author":"SD Ma","year":"2011","unstructured":"Ma, S. D. et al. A new model of Epstein\u2013Barr virus infection reveals an important role for early lytic viral protein expression in the development of lymphomas. J. Virol. 85, 165\u2013177 (2011).","journal-title":"J. Virol."},{"key":"1181_CR205","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1004333","volume":"10","author":"O Antsiferova","year":"2014","unstructured":"Antsiferova, O. et al. Adoptive transfer of EBV specific CD8+ T cell clones can transiently control EBV infection in humanized mice. PLoS Pathog. 10, e1004333 (2014).","journal-title":"PLoS Pathog."},{"key":"1181_CR206","doi-asserted-by":"publisher","first-page":"7976","DOI":"10.1128\/JVI.00770-12","volume":"86","author":"SD Ma","year":"2012","unstructured":"Ma, S. D. et al. An Epstein\u2013Barr virus (EBV) mutant with enhanced BZLF1 expression causes lymphomas with abortive lytic EBV infection in a humanized mouse model. J. Virol. 86, 7976\u20137987 (2012).","journal-title":"J. Virol."},{"key":"1181_CR207","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.chom.2017.06.009","volume":"22","author":"D McHugh","year":"2017","unstructured":"McHugh, D. et al. Persistent KSHV infection increases EBV-associated tumor formation in vivo via enhanced EBV lytic gene expression. Cell Host Microbe 22, 61\u201373 (2017).","journal-title":"Cell Host Microbe"}],"container-title":["Nature Reviews Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41579-025-01181-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41579-025-01181-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41579-025-01181-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T12:03:00Z","timestamp":1757678580000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41579-025-01181-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,25]]},"references-count":207,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["1181"],"URL":"https:\/\/doi.org\/10.1038\/s41579-025-01181-y","relation":{},"ISSN":["1740-1526","1740-1534"],"issn-type":[{"value":"1740-1526","type":"print"},{"value":"1740-1534","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,25]]},"assertion":[{"value":"1 April 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The author declares no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}